Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
2.720
+0.640 (30.77%)
At close: Jan 27, 2026, 4:00 PM EST
2.940
+0.220 (8.09%)
After-hours: Jan 27, 2026, 7:59 PM EST
Acumen Pharmaceuticals Employees
Acumen Pharmaceuticals had 61 employees as of December 31, 2024. The number of employees increased by 9 or 17.31% compared to the previous year.
Employees
61
Change (1Y)
9
Growth (1Y)
17.31%
Revenue / Employee
n/a
Profits / Employee
-$2,186,082
Market Cap
164.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 61 | 9 | 17.31% | 61 | 0 |
| Dec 31, 2023 | 52 | 12 | 30.00% | 51 | 1 |
| Dec 31, 2022 | 40 | 23 | 135.29% | 39 | 1 |
| Dec 31, 2021 | 17 | 10 | 142.86% | 14 | 3 |
| Mar 31, 2021 | 7 | - | - | 7 | 0 |
| Dec 31, 2020 | 7 | - | - | 7 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 279 |
| Sangamo Therapeutics | 183 |
| Sutro Biopharma | 178 |
| Verrica Pharmaceuticals | 71 |
| Cognition Therapeutics | 28 |
| Oncolytics Biotech | 28 |
| Genelux | 24 |
| Whitehawk Therapeutics | 22 |
ABOS News
- 2 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 months ago - Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 6 months ago - Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 - GlobeNewsWire
- 7 months ago - JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform - Business Wire
- 7 months ago - Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025 - GlobeNewsWire